Janssen Seeks Approval of Apalutamide for Non-metastatic Castration-resistant Prostate Cancer

Janssen Seeks Approval of Apalutamide for Non-metastatic Castration-resistant Prostate Cancer
Janssen Biotech has submitted a new drug application  to the U.S. Food and Drug Administration (FDA) for an investigational, next-generation therapy called apalutamide (ARN-509) to treat non-metastatic castration-resistant prostate cancer. Apalutamide is an oral androgen receptor inhibitor that blocks the action of testosterone in prostate cancer cells. The submission was based on data from the

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *